Company Overview - Zeling Bio is a late-stage clinical biotechnology company focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies with first-in-class or best-in-class potential [2] - The company aims to address significant unmet medical needs in the fields of hematologic diseases, oncology, central nervous system, and immune/inflammatory diseases [2] - As of January 5, 2026, Zeling Bio's pipeline includes two core products (Fluorotidine Maleate and Puyisitan Injection), two clinical-stage candidates (ZL-82 and ZL-85), and four preclinical candidates (ZL-65, ZL-69, ZL-59, and ZL-89) [2] Product Pipeline - Fluorotidine Maleate (FM) is a novel triple-target inhibitor for treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, with a focus on JAK2V617F mutations [3] - Puyisitan Maleate (PM) is a next-generation selective HDAC I/IIb inhibitor designed to meet unmet medical needs, featuring a unique non-linear triangular cap structure that enhances binding affinity and exhibits superior inhibitory activity compared to approved HDAC inhibitors [3] Financial Information - Zeling Bio currently has no products approved for commercial sale and has not generated any revenue from product sales [4] - For the fiscal year ending December 31, 2024, and the nine months ending September 30, 2025, the company reported other income and gains of RMB 19.661 million and RMB 7.126 million, respectively [4] - The company incurred operating losses of RMB 91.656 million for the fiscal year ending December 31, 2024, and RMB 119.043 million for the nine months ending September 30, 2025, primarily due to research and development expenses and changes in the carrying amount of redeemable debt [5][7] Industry Overview - Globally, cancer remains a leading cause of morbidity and mortality, with the oncology therapeutics market projected to grow from USD 167 billion in 2020 to USD 262.1 billion by 2024, at a compound annual growth rate (CAGR) of 11.9%, and expected to reach USD 724.9 billion by 2035 [8] - In China, the oncology therapeutics market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [8] - The global myelofibrosis drug market is projected to grow from USD 1.6 billion in 2020 to USD 3 billion by 2024, with a CAGR of 15.9%, and expected to reach USD 6.4 billion by 2030 and USD 11.1 billion by 2035 [14][15]

Company Overview - Zeling Bio is a late-stage clinical biotechnology company focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies with first-in-class or best-in-class potential [4] - The company aims to address significant unmet medical needs in the fields of hematological diseases, oncology, central nervous system, and immune/inflammatory diseases [4] - As of January 5, 2026, Zeling Bio's pipeline includes two core products (Fluorotinib and Puyisitan injection), two clinical-stage candidates (ZL-82 and ZL-85), and four preclinical candidates (ZL-65, ZL-69, ZL-59, and ZL-89) [4] Product Details - Fluorotinib (FM) is a novel triple-target inhibitor for treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, with a focus on JAK2V617F mutations [5] - Puyisitan (PM) is a next-generation selective HDAC I/IIb inhibitor designed to meet unmet medical needs, featuring a unique non-linear triangular cap structure that enhances binding affinity and selectivity compared to approved HDAC inhibitors [5] Financial Information - Zeling Bio has not yet received approval for any products for commercial sale and has not generated any revenue from product sales [7] - For the fiscal year ending December 31, 2024, and the nine months ending September 30, 2025, the company reported other income of RMB 19.66 million and RMB 7.13 million, respectively [8] - The company incurred operating losses of RMB 91.66 million for the fiscal year ending December 31, 2024, and RMB 119.04 million for the nine months ending September 30, 2025, primarily due to R&D expenses and changes in the redemption liability [7][8] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262.1 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and is expected to reach USD 724.9 billion by 2035 [9] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [9] - The global myelofibrosis drug market is anticipated to grow from USD 1.6 billion in 2020 to USD 3 billion by 2024, with a CAGR of 15.9%, and is projected to reach USD 11.1 billion by 2035 [13][16]

Core Viewpoint - Guizhou BaiLing has shown resilience in a challenging pharmaceutical industry, achieving significant improvements in revenue and profit, and is positioned for a new growth cycle due to its strong product portfolio and operational enhancements [1][2]. Financial Performance - In the first half of 2025, Guizhou BaiLing reported revenue of 1.462 billion yuan and a net profit of 51.83 million yuan, indicating a recovery in operations [1]. - The company's cash flow from operating activities increased significantly, with a year-on-year rise of 921.03% [5]. Industry Context - The pharmaceutical industry is experiencing a deep adjustment, with a 1.2% decline in revenue and a 2.8% drop in total profits for large-scale pharmaceutical manufacturing enterprises in China during the same period [2]. Product Strategy - Guizhou BaiLing has developed a diverse product system centered around its "BaiLing Bird" trademark, targeting various health management needs across different age groups [3]. - Key products, such as the Yindan Xinnaotong soft capsule, have shown strong sales growth, with over 100 million yuan in sales in Q1 2025 across major markets [3]. Capacity Expansion - The company is focusing on high-end, intelligent, and green development, achieving a 140% increase in the extraction capacity of traditional Chinese medicine to 60,000 tons per year [4]. - The renovation of the granule production facility is expected to double the annual capacity to 900 million bags, improving product yield and reducing packaging material consumption by 25%-30% [4]. Marketing and Sales - Guizhou BaiLing is enhancing its sales efficiency through direct sales reforms and has completed adjustments in 15 provinces [5]. - The company is collaborating with major pharmaceutical distribution firms to increase product coverage and market penetration [5]. Innovation and R&D - The company is advancing its innovation pipeline, with several projects nearing clinical trial phases, including the successful completion of phase III trials for Huanglian Jiedu Wan [6][7]. - Guizhou BaiLing is also exploring international markets, having signed sales agreements with distributors in Southeast Asia and initiated exports of its products [8]. Long-term Growth Potential - The pharmaceutical sector is expected to see a structural shift, with innovation drugs becoming increasingly valuable assets, positioning Guizhou BaiLing favorably for future growth [8].